 shuffl
 share captur posit ep momentum
longer term risk downgrad ew reflect
favor risk/reward profil upgrad ow
write within australian healthcar group
 togeth -intern growth stock domin respect
industri strong momentum reflect rich valuat thought
prudent take stock compar three share rel basi
stock still trade base case least theme chang
 lead product ig exemplifi elev growth tight end market
 market share recoveri driven nucleu profil
current price reflect simplist success
transplant success poc franchis saa strategi lt durat
unit growth enhanc channel evolut three theme rank
order least like coh given earli evid sycl traction
given busi enhanc brightre given longer lead
time need evid success
current price reflect risk
eventu simplist potenti disrupt altern therapi
 potenti advers outcom materi eros
market share due emerg player theme rank
order least like given pressur pd-hemophilia
lower growth specialti given impact cb round back
juli coh given longer lead time new competit
valuat compar favor trade
discount price target trade premium
 trade premium base case valuat
trade line base case trade
premium averag absolut index rel price-to-earnings number
 premium interestingli coh
similar price-to-earnings multipl wherea long-term trade
price-to-earnings premium
near-term rel prefer move coh favor risk/reward profil
upgrad ow given strong busi share price perform
 downgrad ew overnight closest competitor
advanc bionic initi implant recal discuss though
event separ reason stock rate chang today
appreci support
institut investor all-asia
research survey request ballot
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject finra restrict commun subject
compani public appear trade secur held
exhibit coh order prefer
market cap aud mm
averag daili trade volume usd mm
valuat multipl last close
impli multipl ms price
 p/asx gic rel p/asx ex financi
morgan stanley research morgan stanley research estim ep growth benefit
seqiru acquisit averag growth behr ebit vs
exhibit forecast margin expans three compani
exhibit bull case
exhibit base case
exhibit bear case
valuat summari bull base bear scenario
hear aid practic
evolv referr pathway
result faster market growth
captur ci candid
directli hear aid dispens
p-adjust valu show
efficaci phiii trial interim data due
rfviii/rfix franchis
achiev compani guidanc
sale longer
term hizentra take overal
ig market berinert clazakizumab
achiev market share
us eu devic revenu growth
asp pressur gm next
launch nucleu
share lost maintain
domin market posit
audusd assumpt
achiev market ig growth
near term spec product
month mid-teen growth pd-
share rfviii rfix
appli dcf valuat
forecast includ step
us growth rate associ new
product launch decay pa
advent over-the-counter hear aid
reduc number patient
imped funnel
hemophilia five
pa declin idelvion kcentra
sale base case due
competit ig market growth
success launch fcrn
haegarda berinert market
reduct us mask price ii
poc remain market share iii
devic price iv
resuppli volum growth line
exhibit catalyst
expect releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
us ppta data releas
morgan stanley research catalyst estim releas date base last event releas date
exhibit coh catalyst
expect releas
morgan stanley research catalyst estim releas date base last event releas date
exhibit catalyst
fisher paykel investor day nz
morgan stanley research catalyst estim releas date base last event releas date
model chang made follow chang forecast
updat model result follow releas
us unit growth attribut market share gain
market growth overal unit growth ahead mse led us
upgrad ci unit growth
saw fx contract loss compar mse expect
reduct fx contract loss vs model
higher expect contract loss contribut fall ep
includ impact aasb forecast
expect capital-expenditure
acoust revenu mse expect acoust sale
growth return growth onward osia implant roll
ep lower lower ep increas
base case dcf due small posit earn revis
onward ii dcf roll forward
bull case valuat due higher base case
bear case valuat due higher base case
price target due high scenario valuat higher bull
case weight assum bull case weight previous
base case weight unchang bear case weight previous
increas weight bull case see increas likelihood bull
case bear case think market pay premium growth
offer rel broader asx line valuat
methodolog
rate chang coh upgrad overweight equal-weight given coh rel
under-perform see exhibit trade
new price target feel upgrad ow appropri
exhibit chang forecast group level
sale
sale
exhibit chang forecast segment
exhibit mse coh
profit loss mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
posit earn momentum driven nucleu prole launch
price target set use blend methodolog scenario weight assign bull
base bear case valuat
given asx scarciti defens earn growth view continu trade
toward bull case valuat
assign weight bull case base case bear case
base case valu use dcf methodolog wacc lt growth
trade price target
remain robust onth back nucleu
also see upsid risk long-term
sycl acquisit improv referr
rate hear aid channel may
remov bottleneck clinic
see greater sustain unit
growth market posit due
strategi cochlear link sycl
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
hear aid practic
referr pathway result faster
market growth captur ci
candid directli hear aid
launch nucleu prole see
regain share lost maintain
domin market posit audusd
assumpt
advent over-the-counter hear aid reduc
number patient visit formal hear
aid clinicsand imped funnel
reduct aud usd assumpt
aud usd increas base case
product launch everi four year drive
revenu opportun grow instal
post-nucleu sale backwards-compat
processor weaken next-
reimburs restrict us develop
eu strengthen disappoint uptak
new product longer-than-expect
interrupt greater china surgeri
china india
view explan region hierarchi
research highest favor quintil
 stop press deal competitor recal
advanc bionic llc ab notifi relev regulatori bodi recal un-
implant devic initi version hire ultra ultra cochlear implant
devic devic supersed recent approv new version
recal initi upon observ decreas hear perform limit
number hire ultra ultra cochlear implant devic potenti mitig
impact recal new version devic current roll base
date less recipi explant major hire
ultra ultra implant continu function properli
histori shown recal may benefici market share
strong unit growth strong share price perform exhibit
formal includ potenti benefit ab recal
estim stage given expect report acceler unit
growth may captur associ upsid ii dilig
requir part quantifi potenti benefit
exhibit histori advanc bionic recal
firm
pcp yr prior
growth pcp
nearest day prior
nearest day post
unimpl clarion
hiresolut cochlear implant due
potenti presenc moistur
intern circuitri caus
devic stop function
could fail result elev
implant list remov
market patient
follow sign devic failur
intermitt function complet loss
pop
recal action taken
respons two confirm instanc
product experienc
shock sensat day
initi activ devic
chang
model chang made follow chang forecast
updat model result follow releas includ updat
reflect aasb account chang
behr pd product revenu estim increas
due posit revis pd-coag specialti ig back
recombin product higher mse led posit
chang revenu forecast
seqiru result mse expect ebit
compar previou publish estim continu target
ebit seqiru segment
chang led fall ep see low singl
rate chang downgrad equal-weight overweight due valuat
acknowledg clear earn good ep certainti share
price appreci move beyond price target ew rate
exhibit chang forecast group level
exhibit chang forecast segment
exhibit chang forecast behr product
exhibit mse
growth pcp
profit loss us mn
growth pcp
growth pcp
abn extra tax
return asset
return equiti
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
npat may expect top end guidanc though valuat full
price target blend bull base bear case scenario deriv
discount cash ow methodolog assum wacc
termin growth rate appli bull base bear case weight
appli greater weight bull case rel bear case think
market may pay premium growth offer rel broader asx
think benet tight ig
market industri inventori level
low collect plasma ahead
peer therefor posit
suppli underli demand
inventori restock event ig core
product expect drive stock
acknowledg clear
earn good ep certainti
share price appreci move beyond
price target ew rate
appropri
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
p-adjust valu show efcaci
phiii trial interim data due
rfviii/rfix franchis achiev
compani guidanc
sale longer term hizentra take
overal ig market berinert
clazakizumab achiev market
share acute/chrom amr p-adjust
achiev market ig growth
near term spec product
month mid-teen growth pd-coag
deterior global share
rfviii rfix
hemophilia
pa declin idelvion kcentra sale
base case due competit ig
market growth success launch
fcrn haegarda berinert
plasma center cost
rfviii rfix reach sale
reach sale
disrupt
disrupt ig fcrn
disrupt kcentra
disrupt hemophilia
scig share show continu growth
receiv approv bi-weekli dose
hizentra though risk competitor
mainten albumin sale china
pdfviii sale amid increasingli competit
market critic
china india
view explan region hierarchi
research highest favor quintil
expand spot market ig materi
price increas posit phase data
better expect cost efcienc
lead higher gp margin
lower-than-expect adopt next-
gener rcoag product appreci
aud usd chang us
reimburs environ moder ig
chang
chang made forecast note
rate chang downgrad equal-weight overweight due valuat
good ep certainti busi momentum driven
share price excess price target feel ew rate
statist resm cdi reuter rmd ax stock rate equal-weight exchang
rate forecast ratio cdi list share price target convert cdi
exhibit mse
compani data research research estim note provid research coverag list cdi associ underli ordinari share
compani courtesi may includ cdi price target cdi share price aud dollar research report unless otherwis state cdi price target convers calcul use appropri
currenc exchang rate ordinari share versu cdi ratio investor awar calcul take account issu risk associ invest cdi includ limit liquid
vote right dividend volatil currenc exchang rate fluctuat
wide dispers outcom exist
price target base blend bull base bear case scenario valu weight
respect given asx scarciti defens earn growth view
continu trade toward bull case valuat henc scenario weight
base case valu use dcf methodolog wacc lt growth
rate ew
see long durat growth support
larg instal base growth ii
resuppli sale iii on-going oper
good ep certainti busi
momentum driven
share price excess price target
feel ew rate
view descript risk reward theme
us eu devic revenu growth
volum growth pa iv asp
pressur gm next year
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
reduct us mask price ii poc
remain market share iii
devic price iv resuppli volum
growth line devic growth
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
research highest favor quintil
higher market share cpap
faster-than-expect benet recent
round competit bid
advers impact us competit bid
loss cpap market share
eur usd continu deterior
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
wide dispers outcom exist
price target cdi deriv price target use ratio cdi
investor awar calcul take account issu risk
associ invest adr includ limit liquid vote right
dividend volatil currenc exchang rate uctuat
rate ew
see long durat growth support
larg instal base growth ii
resuppli sale iii on-going oper
good ep certainti busi
momentum driven
share price excess price target
feel ew rate
view descript risk reward theme
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
us devic growth higher current
forecast addit small move mask
turn see upsid poc reach
appli dcf valuat
forecast includ step us
growth rate associ new product
launch decay pa long term
bear case assum reduct us
mask price reduct us unit growth
remain intern level pa
poc remain market share
continu penetr obstruct sleep
high growth high-margin mask/dispos
china india
view explan region hierarchi
higher market share cpap
faster-than-expect benet recent
round competit bid
advers impact us competit bid
loss cpap market share
eur usd continu deterior affect
exhibit figur use comparison
histor ep growth benefit seqiru averag growth behr ebit vs group modelwar compani data morgan stanley research estim
